Xspray Pharma publishes Interim report Q4, January – December 2019
PRESS RELEASE February 28, 2020 “One important milestone was reached in June when our production facility in Italy was completed and was able to do a test run. We have now proven that our technology is possible to scale up - and we are the first in the world to manufacture amorphous material in the form of hybrid nanoparticles on a commercial scale. With our technology, we can now develop improved versions of already marketed cancer drugs, especially in the protein kinase inhibitor class, which is a pharmaceutical group with a very high price level.” Per Andersson, CEO Xspray Pharma AB